4- (decahydromethyl- 3- oxo- 1H- cyclopentaquinolinyl)valeric acid

structure given in first source; a catabolite of cholic acid

Also Known As:

(4R)-4-(2,3,4,6,6abeta,7,8,9,9aalpha,9bbeta-decahydro-6abeta-methyl-3-oxo-1H-cyclopenta(f)quinolin-7beta-yl)valeric acid; 32-1328; 4-(decahydro-6-methyl-3-oxo-cyclopenta(f)quinoline-7-yl)valeric acid; DCQVA

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 146
      - 4-(decahydromethyl-3-oxo-1H-cyclopentaquinolinyl)valeric acid: 1
Organic Chemicals: 133
- Carboxylic Acids: 973
  - Acyclic Acids
    - Valerates: 135
      - 4-(decahydromethyl-3-oxo-1H-cyclopentaquinolinyl)valeric acid: 1
Lipids: 114793
- Fatty Acids: 27405
  - Volatile Fatty Acids: 3052
    - Valerates: 135
      - 4-(decahydromethyl-3-oxo-1H-cyclopentaquinolinyl)valeric acid: 1

Related Diseases

1.	Hepatomegaly 07/01/1994 - "Three-week oral administration of 4-(decahydro-6-methyl-3-oxo-cyclopenta(f)quinoline-7-yl)valeric acid (32-1328) in the diet supplemented at concentrations of 0.1% or 0.3% was associated with hepatomegaly and hypotriglyceridemia in male F344 rats. "

Related Drugs and Biologics

1.	4- (decahydromethyl- 3- oxo- 1H- cyclopentaquinolinyl)valeric acid

Related Therapies and Procedures

1.	Oral Administration